ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / PRQR / financials
RNAC (31) AKBA (57) KRRO (44) NATR (68) ⌘ Pro Terminal →

ProQR Therapeutics N.V. (PRQR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.39 -3.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.38

ProQR Therapeutics N.V. (PRQR) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $203.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRQR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRQR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, ProQR Therapeutics N.V. (NASDAQ: PRQR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.39 (-3.47% 1D, market cap $203.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PRQR ranks #248 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRQR compare to RNAC and AKBA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRQR carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RNAC (Cartesian Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $204.2M) and AKBA (Akebia Therapeutics Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 85.0%, cap $205.7M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while AKBA leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRQR?
▼

For ProQR Therapeutics N.V. (PRQR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #248 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.38 (-0.81%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Cash (12)Whales (10)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE PRQR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRQR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY PRQR SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($5.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$1.62-19.1% Next Q
Q2 (-2Q)
59
Grade C$1.31-5.3% Next Q
Q3 (-1Q)
57
Grade C$1.24+12.1% Next Q
Current
54
Grade D+$1.39-0.7% Hist 90D α
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRQR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRQR currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.74) and Max Pain ($1.46) forces dealer call-delta covering toward $2.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRQR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRQR Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How PRQR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$5.7M (0.1% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRQR)

  • ✓Walkthrough of PRQR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PRQR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -15.24%📐 HORIZONTAL RANGE
2026-11-02O $1.40H $1.45L $1.37C $1.39VOL 337.0K
RES: $2.94SUP: $1.19SMA50: $1.74SMA200: $1.69
$2.55$2.18$1.82$1.45$1.09RES $2.94SUP $1.19$1.392026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRQR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRQR Butterfly Map → + Track PRQR →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRQR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRQR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRQR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRQR)

Health Care Rank #248 of 1016 ⚔️ RNAC vs PRQR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRQR vs. RNAC, AKBA, KRRO, NATR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ProQR Therapeutics N.V. (PRQR) ranks #248 by composite RQD confidence (54/100, grade D+) and #576 by equity capitalization ($203.2M). Within this direct 5-issuer industry benchmark cohort, NATR leads on earnings valuation at 11.1x trailing P/E, while AKBA leads on capital efficiency and profitability with 85.0% ROIC and 83.3% gross margin. NATR currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with PRQR at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRQR ACTIVE
ProQR Therapeutics N.V.
D+ 54/100 — — — -3.47% $203.2M Benchmark Subject
RNAC
Cartesian Therapeutics Inc.
E 31/100 — — -35.0% -3.85% $204.2M /rnac-vs-prqr →
AKBA
Akebia Therapeutics Inc.
D+ 57/100 — 83.3% 85.0% -4.81% $205.7M /akba-vs-prqr →
KRRO
Korro Bio Inc.
D 44/100 — — -35.0% +0.81% $209.1M /krro-vs-prqr →
NATR
Nature's Sunshine Products Inc.
C+ 68/100 11.1x 72.4% 28.9% -0.24% $216.1M /natr-vs-prqr →

2. PRQR Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

ProQR Therapeutics N.V. (PRQR) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $203.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. PRQR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRQR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, ProQR Therapeutics N.V. (NASDAQ: PRQR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.39 (-3.47% 1D, market cap $203.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PRQR ranks #248 in composite RQD confidence.

How does PRQR compare to RNAC and AKBA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRQR carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RNAC (Cartesian Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $204.2M) and AKBA (Akebia Therapeutics Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 85.0%, cap $205.7M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while AKBA leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRQR?

For ProQR Therapeutics N.V. (PRQR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #248 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRQR trading relative to its 50-day, 200-day, and 52-week technical levels?

PRQR last traded at $1.39 (-3.47% on volume of 795,149 shares), positioning the stock -20.11% below its 50-day simple moving average ($1.74) and -17.75% below its 200-day simple moving average ($1.69). Across its 52-week range of $1.20 to $2.81, PRQR sits at the 11.8% percentile with a 14-day RSI of 40.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.22 to $1.56).

PRQR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is ProQR Therapeutics N.V. (PRQR)?

In Trailing 12 Months, PRQR converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $5.7M in free cash flow (0.1% FCF margin).

Direct Sub-Reports: PRQR RQD Cockpit PRQR 12M Forecast PRQR Earnings & Move PRQR Dividends & DRIP PRQR Insiders & 13F PRQR Whale Options PRQR Profit Sankey PRQR News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRQR — ProQR Therapeutics N.V.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:17:24Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PRQR carries an RQD score of 54, a letter grade of D+, and the verdict label "Roarable Sell — Weak Fundamentals / Trim." Across its five pillars, the fundamental cash engine scores 12 of 20 (ROIC 0%; FCF yield 0%), indicating no reported return on invested capital or free-cash-flow yield in the source data. Whale/13F flow scores 10 of 20 for institutional accumulation and options positioning. Insider conviction scores 9 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 10 of 20 with a beta of 1.0 and sector sensitivity. Forensic balance sheet scores 13 of 20, supported by an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5. For a prospective investor, the most direct upside driver implied by the data is balance-sheet resilience, which the forensic pillar reflects. The primary tradeoff is that the cash-engine and insider-conviction pillars are weakest, meaning the rating does not point to current earnings or insider signaling as support. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are not available in source data. The overall verdict is that the rating framework leans negative on fundamentals and flow at this snapshot.

Business

ProQR Therapeutics N.V. (PRQR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile section. The company carries a market capitalization of $0.2B per the profile. Customers, products, and revenue model are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, six items reference PRQR:

  • A Simply Wall St stock analysis covering market action and institutional positioning.
  • A MarketBeat item reporting an FY2028 earnings estimate issued by HC Wainwright.
  • A TradingView item citing a Q3'26 earnings revenue estimate of 4.30M USD.
  • A Stock Titan item stating initial AX-0811 trial data are expected in early January 2027.
  • A TradingKey most-active-stocks item referencing U.S. market activity.
  • A MarketBeat item noting PRQR is expected to announce earnings on Thursday.

Key catalyst: the AX-0811 initial trial data timing, expected in early January 2027.

Risk watch items: the reliance on estimates rather than reported results, and the absence of confirmed earnings figures in the source data.

Proprietary signals: none reported in the Butterfly graph.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be mapped from source data. Sector correlations beyond the Health Care classification and the beta of 1.0 are not available in source data. Second-order bottlenecks are not available in source data.

Open Questions

  • What are reported revenue, net income, and cash-flow figures for recent periods, given that the financials section is empty?
  • What is the status and design of the AX-0811 trial, and does the early-January 2027 data timing hold?
  • What are the consensus analyst rating and price targets, given the analyst data section is empty?
  • Who are the institutional and insider holders, and what are their recent position changes?
  • What is the company's cash runway relative to its debt, since cash and debt figures are not provided?

PRQR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ProQR Therapeutics N.V. (PRQR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRQR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRQR Bull vs. Bear Conversation Board — What's Your Call at $1.39?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRQR 🐻 50% BEARISH CONVICTION
1. Pick Your Side on PRQR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.56 (+8.3%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PRQR (D+ • RQD 54/100) a Buy at $1.44?

Welcome to the PRQR (ProQR Therapeutics N.V.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.14 (-20.8%)
Spot @ $1.44

Pump the brakes on PRQR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PRQR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ProQR Therapeutics N.V. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.79 (+24.3%)
Spot @ $1.44

PRQR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PRQR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.44 (52-wk range $1.29 - $1.60), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%